The primary objective was to evaluate the efficacy of MOLEQURE-Gastrointestinal Health in improving gastrointestinal symptoms such as abdominal bloating, indigestion, acidity, discomfort, altered appetite, and bowel irregularity after 28-days who were under clinical diagnosis of Functional Gastrointestinal Disorder (FGID). The mean change in the composite GI symptom score, Gastrointestinal Quality of Life Index (GI-QoLI) and laboratory safety parameters (CBC, liver, and kidney function tests) were assessed after 28 days of treatment with MOLEQURE-Gastrointestinal Health Capsule, twice daily before meals.

Out of 28 participants, 24 have been selected, enrolled and finished the trial. All participants were male and had an average age of 45.91 years. All participants reported experiencing gastrointestinal discomfort and functioning issues. The most common complaints include nausea, indigestion, heartburn, early satiety, stomach pain, discomfort, bloating, and abdominal distension, as well as changed bowel habits such as constipation, diarrhea, or alternating between the two. The test drug therapy resulted in a considerable improvement in GSRS score (65%), acid reflux (65%), abdominal discomfort (65.3%) and indigestion (65.2%). The overall GI-QLI score was 101.08 at baseline, but it improved to 144.91 after treatment. The improvement rate was 43.3 per cent. After treatment, other GI-QLI subsections, such as physical score, were improved by 25.2%; large bowel function by 50.7%; upper tract function by 68.4%; and psychological or emotional score by 22.2%. All hematological and biochemical indicators were within normal ranges and did not change during treatment.   MOLEQURE- Gastrointestinal Health Capsule treatment improved GI functional disorders and boosted Gastrointestinal Quality of Life without causing any side effects. It may be recommended for long-term use for general gastrointestinal dysfunctions such as abdominal pain, bloating, indigestion, acidity, discomfort, disturbed appetite, and stool irregularity.